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ABSTRACT 1 
Overproduction of superoxide anion (•O2-) and O-linked β-N-acetylglucosamine (O-2 
GlcNAc)-modification in the vascular system are contributors to endothelial dysfunction. 3 
This study tested the hypothesis that increased levels of O-GlcNAc-modified proteins 4 
contribute to •O2- production via activation of NADPH oxidase, resulting in impaired 5 
vasodilation. Rat aortic segments and vascular smooth muscle cell (VSMCs) were incubated 6 
with vehicle (methanol) or PUGNAc (100 µM). PUGNAc produced a time-dependent 7 
increase in O-GlcNAc levels in VSMC and decreased endothelium-dependent relaxation, 8 
which was prevented by apocynin and Tiron, suggesting that •O2- contributes to endothelial 9 
dysfunction under augmented O-GlcNAc levels. Aortic segments incubated with PUGNAc 10 
also exhibited increased levels of (ROS), assessed by dihydroethidium fluorescence, and 11 
augmented •O2- production, determined by lucigenin-enhanced chemiluminescence. 12 
Additionally, PUGNAc treatment increased Nox1 and Nox4 protein expression in aorta and 13 
VSMCs. Translocation of p47phox subunit from the cytosol to the membrane was greater in 14 
aortas incubated with PUGNAc. VSMCs displayed increased p22phox protein expression 15 
after PUGNAc incubation, suggesting that NADPH oxidase is activated in conditions where 16 
O-GlcNAc protein levels are increased. In conclusion, O-GlcNAc levels reduce 17 
endothelium-dependent relaxation by overproduction of •O2- via activation of NADPH 18 
oxidase. This may represent an additional mechanism by which augmented O-GlcNAc 19 
levels impair endothelial and vascular function. 20 
Key words: posttranslational modification, oxidative stress, vascular reactivity, 21 
vasodilation, PUGNAc. 22 
23 
INTRODUCTION 1 
Superoxide anion (•O2-) is a key reactive oxygen species (ROS) that plays both 2 
physiological and pathological roles on cellular redox signaling. Excessive production of 3 
•O2- has deleterious effects in the vascular system, contributing to vascular dysfunction 4 
(Munzel et al. 2002; Rabelo et al. 2010; Brieger et al. 2012). Accordingly, oxidative stress 5 
associated with hyperglycemia not only amplifies inflammation-related events but also 6 
worsens endothelial dysfunction. ROS also increase flux in the hexosamine biosynthetic 7 
pathway (HBP), favoring uridine 5′-diphospho-N-acetylglucosamine (UDP-GlcNAc) 8 
synthesis (Rajapakse et al. 2009).  9 
Glycosylation with O-Linked β-N-acetylglucosamine (O-GlcNAc) on serine and 10 
threonine residues of nuclear and cytoplasmic proteins is a post-translational modification 11 
that alters the function of numerous proteins important in vascular function. It is estimated 12 
that between 2% to 5% of the total glucose entering the cell is metabolized via HBP, 13 
culminating in the formation of UDP-GlcNAc, the substrate for O-GlcNAc protein 14 
modification (Love et al. 2005; Ngoh et al. 2011).  15 
Augmented O-GlcNAc levels were described to impair endothelial function in penile 16 
tissue, due inactivation of phosphorylated endothelial nitric oxide synthase (eNOS), in 17 
diabetes-associated erectile dysfunction (Musicki et al. 2005). Impaired endothelial-18 
dependent relaxation along with increased O-GlcNAcylation was also observed in the 19 
vasculature in normoglycemic conditions (Lima et al. 2008), resulting in eNOS-20 
glycosylation (Lima et al. 2009). Yet, inducible nitric oxide synthase (iNOS) is also 21 
suppressed by O-GlcNAc, abolishing acute vascular dysfunction induced by tumor necrosis 22 
factor alpha (TNF-α) (Hilgers et al. 2012). 23 
In cardiomyocytes, increased levels of O-GlcNAc-modified proteins decrease ROS 24 
formation during ischemia/reperfusion, favoring cell survival (Ngoh et al. 2011). In 25 
opposition, in an experimental model of diabetes, high levels of O-GlcNAc proteins create a 1 
pro-oxidative environment in the liver (Dinić et al. 2013). Additionally, O-GlcNAc 2 
inhibition by blocking the rate-limiting enzyme glutamine, fructose-6-phosphate 3 
aminotransferase (GFAT) prevents endothelial dysfunction in cells isolated from human 4 
umbilical veins submitted to hyperglycemic conditions. This effect is associated with 5 
improvement of antioxidant defenses (Rajapakse et al. 2009).  The exactly mechanisms by 6 
which O-GlcNAc interferes with ROS production, and vice-versa, remains a paradox. 7 
Taking into acount that both augmented O-GlcNAc levels and increased ROS 8 
generation alter vascular function, favoring endothelial dysfunction, we tested the 9 
hypothesis that increased O-GlcNAc levels augment •O2- generation via NADPH oxidase 10 
activation, resulting in impaired endothelium-dependent vasodilation.  11 
12 
MATERIALS AND METHODS  1 
 2 
Animals  3 
Male, 14-16 weeks-old Wistar rats were used in the experimental protocols (n = 4-6 4 
for each experimental group). The animals were housed in high-top-filter cages (3 rats per 5 
cage – 48.3 x 33.7 x 25.3 cm) in a room with controlled humidity (45 ± 5 %) and 6 
temperature (21 ± 2°C), and light/dark cycles of 12 h. Animals had free access to food 7 
(commercially available standard rat chow, Purina) and potable tap water. All experimental 8 
procedures were approved by the Ethics Committee on Animal Experiments of the Ribeirao 9 
Preto Medical School, University of Sao Paulo (protocol 013/2013) and are in accordance 10 
with the Guidelines of the Brazilian College of Animal Experimentation (COBEA) and with 11 
the the Guide for the Care and Use of Laboratory Animals, from the National Academic 12 
Press, 1996. 13 
 14 
Tissue Preparation  15 
Rats were euthanized in a carbon dioxide (CO2)
 chamber and the thoracic aorta was 16 
rapidly removed and cleaned of fat and connective tissue in an ice-cold Krebs solution 17 
containing the following salts (in mM): NaCl, 130; NaHCO3, 14.9; KCI, 4.7; KH2PO4, 1.18; 18 
MgSO4 • 7H2O, 1.18; CaCl2 • 2H2O, 1.56; EDTA, 0.026; glucose, 5.5. Aortic segments were 19 
placed in culture multiwell plates containing 5 mL of Dulbecco's Modified Eagle Medium 20 
(DMEM) (GIBCO-BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine 21 
serum (FBS) and 1% penicillin and streptomycin.  Segments were incubated with vehicle 22 
(methanol, 40 uL) or O-(2-Acetamido-2-deoxy-D-glucopyranosylidenamino) N-23 
phenylcarbamate (PUGNAc; 100 µM), in the presence or absence of apocynin (100 µM, 24 
NADPH oxidase inhibitor) or Tiron (100 µM, •O2- scavenger). Incubations were performed 25 
for 6, 12 or 24 h, in a humidified incubator at 37º C and gassed constantly with 95% O2 and 1 
5% CO2. 2 
 3 
VSMCs isolation and culture 4 
Vascular smooth muscle cells (VSMCs) were isolated from rat thoracic aortas, by the 5 
explant technique, as previously described (Ross 1971). Cultures were maintained in 6 
DMEM (GIBCO-BRL, Gaithersburg, MD, USA) supplemented with 10% FBS (Invitrogen, 7 
Grand Island, NY, USA) and 1% penicillin and streptomycin. After maximum confluence 8 
and 24 h removal of serum, cells were incubated with vehicle (methanol) or PUGNAc (100 9 
µM) for 6, 12 or 24 h. Only fourth-passage cells were used in all experiments.  VSMCs were 10 
identified by determination of α-actin expression by fluorescence microscopy, and the 11 
absence of endothelial cells was confirmed by assessment of von Willebrand factor by real-12 
time polymerase chain reaction (RT-PCR; data not shown). 13 
 14 
Immunofluorescence microscopy analysis 15 
O-GlcNAc levels were evaluated in VSMC plated on glass coverslips (5000 cells/cm). 16 
After 24 h in serum-free media, VSMC were incubated with vehicle or PUGNAc (100 μM), 17 
for 24 h. Cells were washed, fixed in 4 % paraformaldehyde for 10 min, permeabilized (0.1 18 
% Nonidet P40) and incubated in blocking buffer [1 % (w/v) BSA in PBS] for 30 min at 19 
room temperature (25° C). Cells were incubated with the primary antibody mouse anti-O-20 
GlcNAc (1:100 dilution), for 1 h at 37° C and counterstained with a FITC-conjugated anti-21 
(mouse IgG) secondary antibody (1:500 dilution; Jackson Immunochemistry) at 4° C 22 
overnight. Cells were then incubated with 4 ,6-diamidino-2-phenyindole (DAP; Sigma) for 23 
20 min to detect nuclei. Coverslips were mounted, and labeled cells were examined using a 24 
Zeiss microscope and software. 25 
Dihydroethidium fluorescence assay 1 
Dihydroethidium (DHE), an indicator of ROS generation, was used in this study as 2 
previously described (Chignalia et al. 2012). Aortic segments were isolated and incubated 3 
with vehicle, PUGNAc (12 or 24 h), or Angiotensin II (1 µM; 30 min, positive control) in 4 
Krebs solution with controlled temperature (37ºC), continuously gassed with a gas mixture 5 
containing CO2 (5%) and O2 (95%). Thereafter, segments of aorta were embedded in tissue 6 
freezing medium snap-frozen and placed in a freezer at -70ºC. The 10µm thick cryosections 7 
were placed on individual glass slides using Cryostat. At the day of the experiment, 8 
cryosections were incubated in a light-protected and humidified chamber with PBS (37°C, 9 
30 min).  After this period, DHE (50 mM in PBS) was topically applied to each tissue 10 
section (37ºC, for 30 min). The images were obtained at excitation⁄emission (nm) 518⁄605, 11 
using an optical microscope (Eclipse 80i, Nikon, Japan) using a 20X objective. The results 12 
are reported as fold of change and compared to the control group.  13 
 14 
Lucigenin-enhanced chemiluminescence 15 
Aortic segments were stimulated with vehicle or PUGNAc (for 12 or 24 h), in culture 16 
conditions. After stimulation, aortas were washed and harvested in lysis buffer [KH2PO4, 20 17 
mM; EGTA 1, mM; aprotinin, 1 µg/mL; leupeptin 1, µg/mL; pepstatin, 1 µg/mL; and 18 
phenylmethylsulfonyl fluoride (PMSF), 1 mM]. Following, 50 µL of the sample were added 19 
to a suspension containing 175 µL of assay buffer [KH2PO4, 50 mM; EGTA, 1 mM; and 20 
sucrose, 150 mM; (pH 7.4)] and lucigenin (5 μM). NADPH (1 µM) was added to the 21 
suspension (300 µL) containing lucigenin. 22 
Luminescence was measured every 18 seconds for 3 min by a luminometer 23 
(AutoLumat LB 953, Berthold), before and after stimulation with NADPH. A buffer blank 24 
was subtracted from each reading. The results are expressed as counts per milligram of 1 
protein and as a percentage of control). 2 
 3 
Western Blotting  4 
Proteins (60 µg) extracted from aorta or VSMCs were separated by electrophoresis, 5 
and Western blots performed as previously described (Lima et al. 2008). Antibodies used 6 
were: anti-O-GlcNAc antibody (1:2000; Pierce Biotechnology); anti-Nox1, anti-Nox4, anti-7 
p47phox or anti-p22phox primary antibodies (1:1000 each; ProSci), incubated for a period of 8 
24 h, at 4 ºC, under constant agitation. After, incubation with the respective secondary 9 
antibodies was performed and signals were developed with chemiluminescence, visualized 10 
by autoradiography, and quantified densitometrically. β-actin [(1:10000), Sigma-Aldrich, 11 
Inc.] was used as a housekeeping protein. Results were normalized to β-actin protein and 12 
expressed as arbitrary units. 13 
 14 
Membrane and cytosol fractionation by ultracentrifugation   15 
The expression of NADPH oxidase p47phox subunit was determined in membrane and 16 
cytosol fractions. Differential centrifugation was used to obtain the membrane and 17 
cytoplasmic fractions. After incubation with vehicle or PUGNAc (12 h), frozen aortic 18 
segments were mechanically pulverized and the resulting powder collected in 1.5 mL plastic 19 
tubes. Thereafter, cell lysis buffer was added and samples were centrifuged (30,000 G, for 20 
20 min at 4 ºC). The supernatant (corresponding to the cytosolic fraction) was removed, and 21 
the pellet was resuspended in modified lysis buffer (KH2PO4, 20 mM; EDTA, 1 mM; 22 
aprotinin, 10 g/mL; leupeptin, 0.5 g/mL; pepstatin, 0.75 g/mL; PMSF, 0.5 mM; and Triton 23 
1%). The pellet (membrane fraction) was resuspended in this solution and then incubated on 24 
ice for 30 min with intermittent vortex. The determination of protein concentration was 1 
performed in both fractions by Bradford method. 2 
 3 
 Translocation of p47phox  4 
Expression of p47phox in cell fractions was determined by Western blot. The ratio 5 
between the expression of p47phox in the membrane and cytosolic fractions, used as an index 6 
of NADPH oxidase activation, was determined using primary anti-p47phox antibody [ProSci, 7 
(1:1000 dilution), 24 h incubation, at 4 °C, under constant agitation]. Results were 8 
normalized by expression of the protein in the cytosolic fraction, and expressed as arbitrary 9 
units.  10 
 11 
 Vascular Reactivity  12 
Vascular function was assessed in thoracic aorta segments (4 mm in length), after 13 
incubation with vehicle or PUGNAc, in the presence or absence of apocynin or Tiron (24 h). 14 
Vascular segments were mounted in myograph chambers (Mulvany-Halpern, model 610M, 15 
Danish Myotech, Aarhus, Denmark) for isometric tension measurements. Vascular reactivity 16 
was determined using a data acquisition system (PowerLab 8/SP - ADInstruments Pty Ltd, 17 
Colorado Springs, USA). Basal tension of the aortic rings were set to 30 mN, and thereafter, 18 
followed by a stabilization period of 60 min in Krebs solution at 37ºC, continuously gassed 19 
with a gas mixture containing CO2 (5%) and O2 (95%). Blood vessel integrity was 20 
determined using KCl (120 mM). Endothelium-dependent relaxation was assessed by 21 
measuring the relaxation response to acetylcholine (ACh: 1 nM to 100 µM) in PE-contracted 22 
vessels (10 µM). 23 
 24 
 25 
Statistical analysis 1 
The results are presented as mean ± SEM (n), where "n" is relative to number of 2 
animals used in experiments. The concentration-response curves were fit using a nonlinear 3 
fitting interactive program (Graph Pad Prism 3.0, GraphPad Software Inc., San Diego, CA) 4 
and two pharmacological parameters were obtained: the maximum effect produced by the 5 
agonist (or Emax) and -log EC50 (or pD2). Statistical analysis of the pD2 and Emax values were 6 
calculated. Statistical analysis of the pD2 and Emax values was calculated. Statistics were 7 
conducted using Student t test or one-way analysis of variance, followed by post-hoc 8 
comparisons using the Newman-Keuls test, as indicated in the legends. Values of P <0.05 9 
were considered statistically significant. 10 
 11 
12 
RESULTS  1 
O-GlcNAc, ROS and endothelium-dependent relaxation response  2 
PUGNAc is a potent inhibitor of O-GlcNAcase and was used to increase O-GlcNAc 3 
protein levels, aiming to investigate the role of O-GlcNAcylation in the vascular function 4 
(Lima et al. 2009; Lima et al. 2011; Lima et al. 2011). PUGNAc incubation effectively 5 
increased global O-GlcNAc levels in VSMC after 6 and 24 hours (Figure 1A). O-GlcNAc 6 
was also augmented after 12 hours of PUGNAC incubation, compared to vehicle, in a 7 
similar manner that 24 hours (data not shown). Treatment of VSMCs with PUGNAc 8 
(100µM) for 24 hours was also determined by immunohistochemistry, where O-9 
GlcNAcylation was still augmented (Figure 1B).  10 
Endothelium-dependent relaxation was assessed by performing concentration-response 11 
curves to ACh in aortas incubated with vehicle (methanol) or PUGNAc (for 12 or 24 h), in 12 
the absence or presence of apocynin (NADPH inhibitor, 24 h) or Tiron (•O2- scavenger, 24 13 
h). No differences in the endothelium-dependent relaxations were observed in aortas treated 14 
with PUGNAc (Emax 88.7 ± 9%; pD2 5.9 ± 0.3) or vehicle (Emax 87.5 ± 6.5%; pD2 6.2 ± 0.2) 15 
for 12 h.  However, PUGNAc incubation for 24 h decreased ACh-induced relaxation (Emax 16 
77.8 ± 3.1%; pD2 6.6 ± 0.1), compared to aortas incubated with vehicle (Emax 94.1 ± 1.9%; 17 
pD2 7.3 ± 0.07).  18 
No differences were observed in vascular reactivity to ACh in aortas treated with 19 
PUGNAc plus apocynin (Emax 86.8 ± 2.2%; pD2 7.5 ± 0.1), when compared to vehicle-20 
incubated aortas, suggesting that NADPH oxidase inhibition prevented vascular dysfunction 21 
under conditions of augmented O-GlcNAc (Figure 2; Table 1). Similar results were 22 
observed when aortas were simultaneously incubated with PUGNAc and Tiron (Emax 88.0 ± 23 
2.5%; pD2 7.2 ± 0.1), showing that •O2- removal by a scavenger agent prevented the 24 
decreased ACh relaxation induced by high levels of O-GlcNAc proteins (Figure 2; Table 1).  25 
 O-GlcNAc induces ROS generation 1 
Dihydroethidium staining and lucigenin-enhanced chemiluminescence assays were 2 
used to elucidate whether O-GlcNAc increases ROS generation in rat aortas (Figures 3A-B 3 
and 3C, respectively). 4 
Treatment with PUGNAc for 12 and 24 h significantly increased vascular ROS 5 
production, compared to vehicle treatment. Additionally, PUGNAc produced a transient 6 
increase of ROS production, since ROS production was lower in aortas treated with 7 
PUGNAc for 24 h, when compared to 12 h. Ang II (30 min) was used as a positive control 8 
in the DHE assay. As expected, aortas treated with Ang II displayed elevated levels of ROS 9 
(Figures 3A-B).  10 
Aortas treated with PUGNAc for 12 h, but not for 24 h, displayed increased 11 
production of •O2-, as determined by lucigenin-enhanced chemiluminescence and compared 12 
to the respective vehicle group (Figure 3C).  13 
 O-GlcNAc protein levels and NADPH oxidase expression/activity  14 
Protein expression of Nox-1, Nox-4, p47phox and p22phox was determined to investigate 15 
whether NADPH oxidase plays a role in ROS production induced by high levels of O-16 
GlcNAc. Nox-1 and Nox-4 protein expression was increased after treatment with PUGNAc 17 
for 12 h in aortas (Figures 4A and 4B) and VSMCs (Figures 4C and 4D). Nox-1 expression 18 
(Figure 4A), but not Nox-4 expression (Figure 4B), was increased in aortas incubated with 19 
PUGNAc for 6, 12 and 24 h when compared to that in the control group. These results show 20 
that increased O-GlcNAc proteins levels, in aorta as well as in VSMCs, modulate the 21 
expression of both Nox-1 and Nox-4. 22 
PUGNAc incubation (12 h) augmented p47phox membrane translocation (Figure 5), 23 
strongly suggesting that increased O-GlcNAc levels leads to NADPH oxidase activation. 24 
Furthermore, we determined p22phox protein expression, which is essential for NADPH 25 
oxidase activation in VSMC. After PUGNAc incubation for 12h, but not for 6 or 24 h, 1 
p22phox protein expression was increased in VSMCs (Figure 6). 2 
3 
DISCUSSION  1 
Recent interest has been devoted to the modulatory effects of O-GlcNAc in the 2 
vasculature, since several signaling pathways that control vascular function are targets for 3 
O-GlcNAc modifications (Hart et al. 2007; Laczy et al. 2009; Lima et al. 2009), as well as 4 
by ROS (Munzel et al. 2002; Rabelo et al. 2010; Brieger et al. 2012). In order to investigate 5 
whether increased levels of O-GlcNAc-modified proteins contribute to •O2- production via 6 
activation of NADPH oxidase, resulting in impaired vasodilation, the experimental design 7 
included strategies to increase O-GlcNAc protein levels in aortas and VSMCs and to 8 
determine whether O-GlcNAcylation effects on vascular function are mediated by ROS.  9 
The major finding of this study was that increased levels of O-GlcNAc, resulting from 10 
OGA inhibition by PUGNAc, culminated in endothelial dysfunction, at least in part by a 11 
mechanism dependent on •O2- overproduction.  This fact was reinforced by vascular 12 
functional studies using Apocynin and Tiron, which prevented endothelial dysfunction 13 
caused by increased O-GlcNAc. Apocynin, an inhibitor of NADPH oxidase, inhibits Nox-1 14 
and Nox-4, decreasing the production of •O2- and subsequent generation of others ROS. 15 
Apocynin has been shown to reduce ROS in various cell types, including VSMC (Touyz et 16 
al. 2008), to inhibit NADPH oxidase complex in aortas from diabetic rats (Rehman et al. 17 
2013), and to restore endothelial function in diabetic rats (Olukman et al. 2010; Taye et al. 18 
2010). Tiron is a recognized non-toxic chelating agent and membrane-permeable 19 
antioxidant, which selectively removes •O2-. Tiron also inhibits apoptosis mediated by 20 
increased ROS levels (Yamada et al. 2003; Yang et al. 2007).  21 
Indeed, increased levels of O-GlcNAc proteins in aortic segments from Wistar rats 22 
lead to increased production of •O2-, as demonstrated by DHE stain. Activation of the HBP, 23 
which increases the production of UDP-GlcNAc and stimulates O-GlcNAc modification of 24 
proteins, has been shown to induce ROS generation and oxidative stress in mesangial cells 25 
(Singh et al. 2007). Increased O-GlcNAc proteins also promote ROS production in renal 1 
mesangial cells incubated in high glucose conditions, or upon glucosamine stimulation 2 
(Goldberg et al. 2011). Furthermore, accumulation of advanced glycation end products 3 
triggers ROS generation and nuclear O-GlcNAc activation in cardiac myocytes (Li et al. 4 
2007).  5 
Of importance, O-GlcNAc-induced ROS production peaked at 12 h, the same time 6 
frame observed for •O2- production which relied on NADPH oxidase activity. The NADPH 7 
oxidase complex is a major source of •O2- present in vascular cells and has membrane-bound 8 
subunits (Nox-1, Nox-2, Nox-4 and Nox-5, p22phox) and cytosolic subunit (p47phox, p67phox) 9 
(Martinez-Revelles et al. 2013). Nox-1 and Nox-4 expression in VSMC and aorta, as well as 10 
p22phox subunit in VSMC, also peaked at 12 h.   11 
It is known that Nox-1 activity and, consequently, the production of •O2- is regulated 12 
by the subunit p47phox and p22phox (Geiszt 2006; Lassegue et al. 2012), since the p22phox and 13 
p47phox subunits are essential for the activity of NADPH oxidase, in VSMC (Niu et al. 14 
2010). Nox-4 activation requires only association with p22phox subunit (Ambasta et al. 2004; 15 
Martyn et al. 2006), not being controlled by the cytosolic subunits of the NADPH oxidase 16 
(Martyn et al. 2006), and p22phox subunit is required to generate a Nox-4-dependent radical 17 
(Ambasta et al. 2004). Our results demonstrate that increased production of •O2- upon 18 
PUGNAc stimulation is due to increased levels of O-GlcNAc, through increased protein 19 
expression of Nox-1 and Nox-4 enzymes. Furthermore, O-GlcNAcylation increased p22phox 20 
protein expression after 12 h of PUGNAc incubation.  21 
Zachara and colleagues, in 2016,{Lee, 2016 #774} elegantly showed that oxidative 22 
stress induces O-GlcNAcylation. Indeed, these authors discussed that O-GlcNAcylation is 23 
one component of the cellular stress response that is relevant to a variety of models of injury 24 
in several cell lines and tissue types, and upon oxidative stress proteins related to cellular 25 
injury. Here, we showed, in a humbler manner, the opposite direction of this same equation. 1 
We demonstrated that increased O-GlcNAcylation may induce oxidative stress.  Besides de 2 
subunits of NADPH oxidase were increased after PUGNAC incubation, one possibility was 3 
that activity of this enzyme may or not be altered. Of importance, translocation of p47phox 4 
subunit was also assessed at 12 h, demonstrating increased activity of NADPH after 12 h of 5 
PUGNAc incubation in aorta. Evidence suggests that phosphorylation of the three serine 6 
residues in p47phox is crucial for translocation of the cytosolic components and assembly of 7 
the active NADPH oxidase (Johnson et al. 1998; Ago et al. 1999).  8 
Many phosphorylation sites are also known glycosylation sites, and this mutual 9 
assignment can produce different activities or change the stability of the target protein (Hart 10 
et al. 1995; Hart et al. 1996; Hu et al. 2010; Zeidan et al. 2010). In this sense, Goldberg and 11 
colleagues (2011) speculated that O-GlcNAc increases the phosphorylation of the NADPH 12 
oxidase subunit p47phox, through p38 MAPK activation, and up-regulates the expression of 13 
the NADPH oxidase subunit Nox4, in glomerular mesangial cells (Goldberg et al. 2006). It 14 
remains to be elucidated whether p22phox is a target for O-GlcNAc.  15 
ROS are produced in several cells of the cardiovascular system, including cardiac 16 
myocytes, endothelial and smooth muscle cells and are tightly regulated by antioxidants and 17 
oxidants including hydrogen peroxide (H2O2), •O2-, hydroxyl radical (OH-), among others 18 
(Touyz et al. 2008; Silva et al. 2013). Under oxidative stress, ROS production can lead to 19 
endothelial dysfunction, by decreasing NO, which reacts with •O2- to form •ONOO- (Li et al. 20 
2005; Silva et al. 2013), increases contractility, vascular smooth muscle cell growth, 21 
monocyte migration, lipid peroxidation, inflammation, and other processes contributing to 22 
cardiovascular damage (Pashkow 2011; Satoh et al. 2011; Touyz et al. 2011).  23 
Since •O2- production was increased by augmented O-GlcNAc levels, and 24 
endothelium-dependent relaxation was decreased, one may speculate that this radical may be 25 
reacting with NO, thereby contributing to impaired endothelium-dependent relaxation under 1 
PUGNAc treatment. In fact, decreased endothelial-dependent relaxation observed in this 2 
study does not appears to be exclusively dependent on decreased availability of NO. By 3 
evaluating the effects of PUGNAc in a time-course manner, one can observed that the peak 4 
of •O2- overproduction occurs at 12 hours, and that ROS production is maintained for 24 5 
hours, whereas endothelium-dependent relaxation is decreased only after 24 hours. This may 6 
indicate that •O2- overproduction, via NADPH oxidase activation, is an initial and essential 7 
event to increase ROS production, resulting in vascular dysfunction.  8 
On this regard, the enhancement of •O2- significantly contributes to the instability of 9 
endothelium derived relaxation factors (EDRF), as initially demonstrated by Moncada and 10 
colleagues in 1986 (Gryglewski, Palmer et al. 1986).  Here, vascular function wass initially 11 
challenged by an oxidative burst at 12 hours, with massive production of •O2-. In the other 12 
hand, the impairment of endothelium-dependent relaxation occurred in a different time-13 
frame than oxidative stress enhancement, and was observed after 24 hours, but still 14 
prevented by anti-oxidant drugs.   One possibility is that besides the short half-life of •O2-, 15 
this anion rapidly combines with NO to form more stable products, such as ONOO-, a potent 16 
cytotoxic oxidant, which may cause oxidative damage in endothelial cells through several 17 
mechanisms including nitration of tyrosine residues of proteins, peroxidation of lipids, 18 
degradation of DNA, oligonucleosomal fragments, among others (Hemnani and Parihar 19 
1998).  20 
Another possibility, not addressed here, is that O-GlcNAc may affect anti-oxidant 21 
mechanism, and even if •O2- production was recovered after 24 hours, this protective cellular 22 
mechanism may still be disrupted. For example, glutathione peroxidase 1, an anti-23 
oxidant enzyme, is modified with O-GlcNAc on its C-terminus in rat VSMCs and HEK293 24 
cells, under hyperglycemic conditions (Yang, Park et al. 2010). Still, other possibility is that 25 
other sources of •O2- production, for example the uncoupling of eNOS, may be activated 1 
over 24 hours (Karbach, Wenzel et al. 2014).  2 
Considerable data have shown that O-GlcNAc regulates cellular stress responses, 3 
favoring cell survival (Groves et al. 2013). Of importance, inhibition of OGA with PUGNAc 4 
significantly reduced ROS in rat cardiomyocytes, (Ngoh et al. 2011) corroborating data 5 
showing that O-GlcNAc seems to be protective in the heart. Several aspects must be 6 
considered in this interplay between O-GlcNAc and ROS generation: acute vs. chronic 7 
effects of O-GlcNAcylation, the initial cellular conditions when components of the O-8 
GlcNAc system are manipulated, global vs. localized increases of O-GlcNAcylation and the 9 
specific proteins that are O-GlcNAc-modified in different tissues.  10 
The results show here also suggest that other mechanisms are involved in the critical 11 
interplay between O-GlcNAcylation and ROS generation, in the cardiovascular system. 12 
Indeed, evidence from the literature, along with our data, strongly suggests an interplay 13 
between O-GlcNAcylation and ROS generation, and vice-versa, in the cardiovascular 14 
system. Hence, both ROS and O-GlcNAc are crucial, not only to control vascular function in 15 
physiological conditions, but also under pathological states where ROS and O-GlcNAc are 16 
enhanced, culminating in cellular injury and organ dysfunction. Future studies, evaluating 17 
other ROS products, as well as other sources of ROS, will contribute to the understanding of 18 
the relationship between ROS and O-GlcNAc and whether this interplay also occurs in in 19 
vivo conditions. 20 
 21 
 22 
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LEGEND TO FIGURES  1 
Figure 1: O-GlcNAc levels are increased in VSMC after PUGNAc incubation. A) O-2 
GlcNAc levels were evaluated in VSMC incubated with vehicle (methanol, white bar) or 3 
PUGNAc (100 μM; black bars) for 15 min, 30 min, 1 h, 6 h or 24 h. Results are expressed as 4 
mean ± SEM. n = 5-6, for each experimental group. * P ≤ 0.05 vs. vehicle. (One-way 5 
analysis of variance, followed by post hoc comparisons using the Newman-Keuls test). B) 6 
Phase contrast microscopy demonstrating that treatment with PugNAc (bottom pictures) 7 
increases O-GlcNAc-proteins in cultured VSMCs. Blue, DAPI stained nuclei; green, O-8 
GlcNAc-modified proteins [FITC-labeled second antibody (anti-mouse IgG) and primary 9 
anti-O-GlcNAc. Magnification x20. 10 
 11 
Figure 2. O-GlcNAc decreases endothelium-dependent relaxation in aorta, an effect 12 
prevented by apocynin and Tiron. Concentration-response curves to ACh, to assess 13 
endothelium-dependent relaxation, were performed in aortic segments incubated with 14 
vehicle (methanol, white square) or PUGNAc, in the absence (white circle) or presence of 15 
apocynin (black square) or Tiron (black circle). n = 6 for each experimental group. Results 16 
are expressed as mean ± SEM. Experimental values of the relaxation induced by ACh were 17 
calculated relative to the maximal changes from the contraction produced by PE, which was 18 
taken as 100%. * P ≤ 0.05 vs. vehicle. (One-way analysis of variance, followed by post hoc 19 
comparisons using the Newman-Keuls test). 20 
 21 
Figure 3. Increased O-GlcNAc levels positively modulate ROS generation in 22 
aortic segments. Frozen aortic sections were incubated with Dihydroethidium (DHE, 50 23 
mM, green) for 30 min to evaluate ROS generation (red). A) Fluorescence measurement 24 
charts in each experimental condition: vehicle (white bar), incubation with PUGNAc (black 25 
bars, 12 or 24 h) or with Ang II (chess bar, 30 min). B) Representative photos of each 26 
assessed group. C)  PUGNAc effect on •O2- generation was assessed with lucigenin, after 12 1 
or 24 h of stimulation. Results are expressed as mean ± SEM. n = 5 for each experimental 2 
group. * P ≤ 0.05 vs. vehicle (methanol); † P ≤ 0.05 vs. PUGNAc 12 h. (Analysis of 3 
variance and Student's t-test, post hoc comparisons were performed by the Newman-Keuls). 4 
 5 
Figure 4. O-GlcNAc increases Nox-1 and Nox-4 protein expression both in aorta 6 
and VSMC. Aortas (A and B) or VSMCs (C and D) were incubated with vehicle (methanol, 7 
white bar) or PUGNAc (black bar; 6, 12 or 24 h). Protein expression of A) Nox-1 and B) 8 
Nox-4 in rat thoracic aortas, and C) Nox-1 and D) Nox-4 in VSMCs, was determined. 9 
Results are expressed as mean ± SEM. n = 4-5 for each experimental group. * P ≤ 0.05 vs. 10 
vehicle. (Analysis of variance and Student's t-test, post hoc comparisons were performed by 11 
the Newman-Keuls). 12 
 13 
Figure 5. O-GlcNAc increases translocation of p47phox from the cytosol to the 14 
membrane: NADPH activity in aorta. Aortas were incubated with vehicle (methanol, 15 
white bar) or PUGNAc (black bars; 12 h) and subjected to ultracentrifugation protocols to 16 
isolate membrane and cytosolic fractions. A) representative photos and B) quantification of 17 
p47phox protein expression in the membrane over cytosolic fractions. Results are expressed as 18 
mean ± SEM. n = 4-5 for each experimental group. * P ≤ 0.05 vs. vehicle. (One-sample t 19 
test). 20 
 21 
Figure 6. O-GlcNAc increases p22phox protein expression in VSMCs. VSMCs were 22 
incubated with vehicle (methanol, white bar) or PUGNAc (black bar; 6, 12 or 24 h) and 23 
p22phox protein expression was determined. On the top, representative Western blot images 24 
of p22phox and β-actin; on the bottom, bar graph show the relative p22phox proteins after 25 
normalization to β-actin expression. Results are expressed as mean ± SEM. n = 4-5 for each 1 
experimental group. * P ≤ 0.05 vs. vehicle. (Analysis of variance and Student's t-test, post 2 
hoc comparisons were performed by the Newman-Keuls).3 
LEGEND TO TABLES  1 
 2 
Table I. Emax and pD2 values for ACh in rat aortas incubated with vehicle or 3 
PUGNAc, in the presence or absence of apocynin or Tiron (24 h). 4 
 5 
Group Emax pD2 
Vehicle 94.1 ± 1.9 7.3 ± 0.07 
PUGNAc 77.8 ± 3.1* 6.6 ± 0.10* 
PUGNAc + apocynin 86.8 ± 2.2 † 7.5 ± 0.10 † 
PUGNAc + Tiron  88.0 ± 2.5 † 7.2 ± 0.10 † 
 6 
Results are presented as mean ± SEM (n = 6 in each group). The potency of the 7 
agonist is expressed as pD2 (negative logarithm of the molar concentration that produces 8 
50% maximal response). Sigmoidal curves were drawn to determine the pD2 values. 9 
Statistical significance of data was determined by analysis of variance (ANOVA one-way) 10 
followed by the Newman-Keuls post-test * P <0.05 vs. vehicle. † P<0.05 vs. PUGNAc. 11 
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